See original article here

PARIS and TORONTOJan. 4, 2018 /PRNewswire/ — Servier and Treventis announce strategic research partnership in targeting misfolded proteins implicated in neurodegenerative diseases. The collaboration covers a large drug discovery program targeting both tau and amyloïde-β (Aβ), two key proteins involved in Alzheimer’s disease. This therapeutic strategy aims to provide patients with a drug that slows the progression of pathology in the brain, thereby minimizing functional decline through a disease-modifying mechanism.

Servier and Treventis will jointly develop compounds that act as inhibitors of tau and Ab oligomer formation, identified by Treventis’ Common Conformational Morphology (CCM) platform technology. The collaboration will also include the development and validation of translational biomarkers to support the preclinical program, allow the characterization and selection of patient populations and track disease progression in the clinic.

Under the terms of the agreement, Treventis and Servier will co-develop the programs until selection of a Phase 1 candidate. Servier will fund all research costs and will have exclusive worldwide rights to develop and commercialize any selected compounds.

“Servier has been engaged in the development of therapies targeting neurodegenerative disorders for more than a decade. We very much hope that this new collaboration will allow us to answer the huge unmet patient need for disease-modifying treatment of Alzheimer’s disease, thanks to Treventis’ unique and innovative technology,” said Christian de Bodinat, Director of Servier’s Center of Therapeutic Innovation in neuropsychiatry. “We are very excited to be part of one of the first programs employing a dual approach in this field.”

With more than 10 years of experience in this field, Treventis has a unique and revolutionary process for identifying small molecules to neutralize misfolded proteins, such as those implicated in Alzheimer’s (beta-amyloid and tau) and in other neurodegenerative diseases (Parkinson’s disease, Amyotrophic Lateral Sclerosis).

Therapeutic targeting of intrinsically disordered proteins such as tau and Aβ peptide by small molecules is a major challenge because of their heterogeneous conformational properties. Treventis scientists identified a common binding site based on epitope commonality between multiple misfolded amyloid proteins. This information was used to create CCM, a proprietary methodology for constructing models of the earliest stages of protein misfolding. Using CCM for in silico screening allows for the identification and optimization of numerous classes of potent, drug-like compounds –making structure-based design a reality for anti-amyloid drug discovery.

We are very excited to work with Servier to progress new therapies for neurodegenerative diseases,” said L. William McIntosh, Board Chairman of Treventis. “We believe that the combination of Treventis’ innovative platforms and technologies with Servier’s deep expertise in central nervous system drug development has significant potential to rapidly advance new treatments for patients in need.

About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes, as well as by its activities in high-quality generic drugs.

Servier has a solid commitment to neuropsychiatry and to proposing innovative therapies to patients suffering from neurological conditions. Its research teams are investigating new ways of treating diseases such as Alzheimer’s and Parkinson’s, as well as a broad range of neurodegenerative disorders, by targeting the toxic proteins that lead to neuron degeneration. The priority is to focus on the causes of the diseases rather than their symptoms. Currently, there are 5 projects at different stages of research and development in this promising area. This portfolio of innovative treatments is being developed with academic and industrial partners worldwide.

More information:

Find us on Social Media: LinkedIn | Facebook | Twitter

About Treventis
Treventis is headquartered in Pennsylvania and has research operations in Halifax and Toronto, Canada. The company is focused on the discovery and development of disease-modifying small molecule drugs for a variety of protein misfolding diseases including Alzheimer’s. In addition to its therapeutic programs, Treventis has a novel diagnostic approach for early diagnosis and monitoring treatment effects in Alzheimer’s disease. More information:

Press contacts:

Sonia MARQUES: – Tél. : +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Karine BOUSSEAU: – Tél. : +33 (0)1 55 72 60 37

Chris BARDEN:  Tel : +1 (647) 228-1276


SOURCE Treventis


See original Entrevestor post here

Appili Therapeutics has struck an agreement to work on a vaccine that could protect people against a potential bioterror threat.

The Halifax drug discovery company said Monday it signed a licence agreement with the National Research Council of Canada to help develop ATI-1701, to vaccinate against tularemia. The vaccine will protect against bacteria called Francisella tularensis, which can cause tularemia, a highly infectious disease also known as rabbit fever.

People can become infected with tularemia through tick and deer fly bites, drinking infected water or by simply inhaling the disease if it becomes airborne. This is why the U.S. Centers for Disease Control and Prevention lists F. Tularensis (the bacteria that causes the disease) as a Category A pathogen, a bacteria that poses the highest threat to national security and public health.

“Francisella tularensis is a very infectious bacteria,” Sean McBride, Appili vice-president of business development, said in the announcement. “A small number (of bacteria) can cause tularemia disease. If used as a weapon, the bacteria would likely be made airborne for exposure by inhalation.”

He added: “People who inhale an infectious aerosol would generally experience severe respiratory illness, including life-threatening pneumonia and systemic infection, if they are not treated,”

Aerosolized F. tularensis was studied by the Soviet Union during the Second World War and the Cold War for military purposes. The Soviets also developed a vaccine, but with limited effectiveness.

The NRC’s ATI-1701 compound was developed through genetic engineering and has shown a strong immune response to the F. tularensis strain.

“The NRC has developed an elegant attenuated vaccine that is showing dramatic results, better than the current vaccination,” Appili CEO Kevin Sullivan said in an interview.

Wayne Conlan led the team that developed NRC’s ATI-1701 compound. In the statement, he said: “It is very rewarding to see our team’s research on this vaccine progress from our labs to the next stage of development. We are delighted to partner with Appili on this important program designed to protect the health of Canadians exposed to bioterror threats.”

Part of the funding to develop the vaccine is from the Defense Threat Reduction Agency, a part of the U.S. Department of Defense, which has invested $6.2 million into a five-year program to develop the tularemia vaccine.

The licence agreement with the NRC grants Appili — which has raised money from Innovacorp and through the investment boutique Bloom Burton  & Co. — exclusive worldwide rights to develop and commercialize the tularemia vaccine.

Under the agreement, Appili is responsible for the preclinical and clinical testing to evaluate the safety of the ATI-1701 vaccine in humans as per the guidelines from the Food and Drug Administration and Health Canada.

The vaccine won’t be commercially available for another 3-5 years but Sullivan says this is the right step to hinder the development of a tularemia bioweapon.

“It’s one of the goals of the West to develop the tularemia vaccine in case there is a bioterror attack,” said Sullivan. “We want to minimize the threat of a bioterror weapon to a point where the adversary doesn’t even bother making one.”

See original CBC article here

The Nova Scotia government is touting new hospital software it says can better predict breast cancer risk, but the province is not routinely sharing the results with patients or their family doctors.

In October, software designed by Nova Scotia company Densitas was installed in hospitals throughout the province to automatically record breast density during mammograms.

The idea is to use the technology instead of relying on a radiologist’s eyes because, like cancer, dense breast tissue appears white in mammograms, making it difficult for radiologists to see. A woman with dense breasts also has more dense tissue than fatty, and that means her chances of getting cancer are higher.

But unless a woman specifically asks her doctor to request the breast density recordings from the radiologists, the results are filed away.

Cheryl Stewart-Walsh said women deserve to know that information, along with the potential health risks of having dense breasts.

The Dartmouth, N.S., woman said she still wonders about her examination four years ago. She had noticed some lumps and was told she had dense breasts, but her mammogram came back clear.

Knowledge is power

“If somebody had said to me back then, ‘You have dense breast tissue and it means that you need to be more vigilant because you have a higher risk of breast cancer,’ I would have been doing more regular exams,” she said.

This spring, the 39-year-old noticed a lump in the same spot doctors had first examined. Within weeks, she was diagnosed with breast cancer and has since undergone a lumpectomy, 18 weeks of chemotherapy and 21 rounds of radiation. She just completed cancer treatment last month.

Paula Gordon, a Vancouver-based radiologist with the national advocacy group Dense Breasts Canada, said women deserve to know their breast-density information so they can be more vigilant with self-exams.

Cancer risks

“Knowing your breast density is like knowing that you have high blood pressure or that you have high cholesterol,” Gordon said. “Can you imagine a family doctor taking somebody’s blood pressure and finding it high, and not sharing that information with the patient?”

Approximately 43 per cent of women aged 40 to 74 have dense breast tissue, according to Gordon’s group, which means more than 100,000 women in Nova Scotia could be affected.

Some women with dense breasts have four to six times the risk of getting breast cancer compared with women who don’t have dense breasts, according to the Canadian Cancer Society.

Dr Paula Gordon

Dr. Paula Gordon says women across Canada are being left in the dark.

The province says it eventually wants to provide its new software-generated breast-density information automatically to doctors and patients. However, there is currently no “mechanism” or timeline to do so, according to Dr. Sian Iles, a radiologist and medical adviser for the Nova Scotia breast screening program, which is run by Nova Scotia’s Department of Health.

“We have got plans but we haven’t been able to implement that yet,” Iles said. “It’s a very complex health-care system. We’re not in charge of all the variables.”

Years have been spent standardizing the reporting of breast density, Iles said, and every mammogram in Nova Scotia now leads to an automated breast density report.

Each province has different rules around testing and reporting breast density. Quebec requires that a woman’s breast density information be reported, but only to her doctor.

Other provinces, like Ontario and P.E.I., usually require that the information be passed on to a woman’s doctor, and that the patient be informed if her density is over 75 per cent, which is considered extreme.


New software automatically records breast density on a woman’s mammogram. (Patrick Callaghan/CBC)

Until recently, Nova Scotia was the only province that did not require radiologists to record breast density, according to Dense Breasts Canada.

Gordon, the medical adviser with Dense Breasts Canada, said 50 per cent of breast cancers in women with dense breasts are missed on mammograms.

“We see these patients in the clinic,” said Gordon. “They come with a lump in their breast that they have found, sometimes within weeks or months of a negative screening mammogram.

“The lump in their breast … turns out to be not just a cancer, but sometimes a sizable cancer.”


See original ENTREVESTOR article here

BlueLight Analytics Inc., a Halifax company that helps ensure the proper curing of dental fillings, has partnered with industrial giant 3M Corp. to greatly expand the startup’s sales power in the U.S.

The two companies announced the partnership on Wednesday. Under the terms of the deal, 3M salespeople will offer BlueLight’s flagship product checkMARC, which helps to ensure dentists use their curing light for just the right length of time when curing resin-based fillings.

“This partnership gives us a national presence in the U.S., which is the biggest market for us,” BlueLight chief executive J.P. Furey said in a phone interview from Dallas, where he’s been training 3M sales teams.

“It’s definitely a huge milestone for the company and we think it’s the first of many as we expand globally.”

Growing out of research at Dalhousie University, BlueLight began about seven years ago to solve a problem few dentists spoke about. The lights they use to cure resin vary greatly, and each model has to be used for just the right amount of time to cure the resin properly. Too long a time could adversely affect the tooth and too little would leave the resin only partially cured.

BlueLight developed the checkMARC system, which can test and identify the efficacy of a dental office’s curing lights. Based on the results, 3M will review the light-curing protocols currently in practice. The Minnesota-based company said it can then work with the dental clinic to identify evidence-based opportunities to improve clinical outcomes and patient satisfaction.

BlueLight said that before its technology was commercialized, there was a “quality gap” in the market for dental fillings — a multi-billion-dollar market that is the cornerstone of every dental clinic.

Almost two years ago, BlueLight announced a partnership with the Canadian division of 3M to jointly market checkMARC across Canada, and that led to a broader relationship.

“The last announcement was Canadian-centric,” said Furey, an accountant who became the company’s CEO in the autumn of 2015. “Since then a lot has happened and it has led to pilots in the U.S. and now this deal, which covers the whole U.S. It’s five to 10 times bigger than the Canadian market.”

He added that he and three other BlueLight representatives are in the U.S. this week, training 3M sales representatives in checkMARC. The salespeople are expected to begin offering the service to clients as early as this week.

The relationship with 3M is already expanding beyond North America. The Halifax company has been working with 3M in Australia, New Zealand and Germany.

“As the market leader for restorative dentistry, 3M is dedicated to providing dental professionals the latest technologies and innovations in dentistry to improve practice productivity,” the Minnesota company said in a statement.

BlueLight has partnerships with a few large companies. Also in 2015, it announced a partnership with Henry Schein, the Melville, New York-based medical product distributor whose 2014 sales exceeded US$10 billion.


See original article here

DM-Density personalized breast density reporting software will be offered via vendor neutral artificial intelligence distribution platform

Chicago, IL – November 26, 2017 – Advanced breast imaging analytics provider, Densitas, today announced that it now offers its automated breast density software through EnvoyAI’s scalable distribution platform to facilitate streamlined deployment of its flagship product within hospital networks and clinics. The software, DM-Density, helps radiologists provide tailored, patient-specific follow-up care.

“We’re pleased to offer hospitals and physicians the opportunity to use Densitas’ breast density software either on-premise or in the cloud. We’re committed to providing our customer base with secure access to innovative AI products globally,” said Misha Herscu, CEO, EnvoyAI. “Densitas’ breast density software is a welcome addition to the many clinically useful applications available on the EnvoyAI Exchange.”

“We’re pleased to partner with EnvoyAI to streamline deployment of our automated breast density software to empower health systems to standardize high quality care for women and improve workflow,” said Mohamed Abdolell, CEO, Densitas. “The EnvoyAI platform provides a unique opportunity to rapidly expand our footprint so these important outcomes can be achieved.”

DM-Density is a machine learning application that provides on demand automated breast density assessments at point-of-care. The software analyzes standard digital mammograms and integrates seamlessly with PACS systems. The reports provide radiologists with insights to make better follow-up care decisions consistently and confidently.

About Densitas

Densitas develops machine learning technologies that deliver actionable information for personalized breast health. The technologies address the key challenges facing breast screening, including mammography quality, workflow, compliance and costs, with the aim of improving patient health efficiently and effectively. Densitas has received regulatory clearance to sell its automated breast density assessment software in Canada and the European Union. Learn more.

About EnvoyAI 

EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end users. EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer ­­­intellectual property. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.


Media Contact:Alex MorrisDirector, Programs and Regulatory Affairs

See original Entrevestor Article here

By Peter Moreira

Halifax-based PhotoDynamic Inc. will put its plaque-killing oral health product through clinical trials in the next month, the outcome of which will shape its strategy for the next few years.

The company will test its product with 20 patients at the Forsyth Institute in Boston, one of the world’s most prestigious research facilities in the field of oral health. If it gets good results from these tests, the company plans to work closely with a Fortune 100 consumer products company to bring the product to market.

That product — called PD Foam and PD Tray — is a system that kills plaque buildup on teeth through a combination of light and an extract from a plant that grows wild in Nova Scotia. Because the plant is known to be safe for human consumption, the product has a relatively simple regulatory path. Its initial target market is the one-fifth of the population who suffer from excessive plaque buildup on their teeth regardless of how much they brush.

“We’ll start in a few weeks and have the results by January,” said CEO Martin Greenwood in an interview. “If the results are good, it will be easy to raise our next round (of financing) and then we’ll be moving on to a larger trial.”

In the spring of 2016, PhotoDynamic raised $250,000 in equity funding through the First Angel Network, and supplemented that capital with money from government programs. The company, which grew out of research by Acadia University professor Sherri McFarland, has remained lean with four employees and used the FAN money to build a working prototype.

PhotoDynamic has developed foam made from the plant extract, which the user places in the top and bottom trays of a special mouthpiece, like a mouthguard a hockey player would wear and which contains LED lights. Users turn on the lights, place the device in their mouth for one minute, and the plaque is gone.

So far the system has killed plaque successfully in a petri dish and in animal tests, but surprises can crop up in human trials, Greenwood said. For example, 10 subjects will be given the PhotoDynamic device and the other 10 a placebo, to establish a clear gap between plaque buildup in the two groups. If a few of the 10 placebo-takers obsessively brush their teeth all day, it could skew the results.

Greenwood feels confident in the PD Foam and Tray and believes the company has positioned itself to proceed promptly with its commercialization. It has built up a strong working relationship with its multinational partner (whom Greenwood declines to name publicly), and that could help bring the product to market.

PhotoDynamic has also strengthened its board, recently adding former Johnson & Johnson consumer products CTO Neal Matheson and Barry Turner, a former vice-president of global complimentary medicines with Warner-Lambert.

Assuming the trials are successful, Greenwood plans to raise about $1.5 million to take the company through the next two years. In that period he hopes to fine-tune the engineering of the product and carry out more thorough clinical trials, involving about 75-125 people over six months.

Then Greenwood plans to sell the oral health product to a large company that can develop it, and PhotoDynamic will use the proceeds to work on other applications for the plant extract.

“The way to really grow this company is to say, ‘We’re the people that can really take this technology to its potential,’” he said. “Let us be the R&D hub. . . . What we want to do is hit a home run and take the funds and reinvest them into the next one.”

See original Entrevestor article here

By Peter Moreira

With its indoor farm in Guelph, Ont., nearing completion, TruLeaf Sustainable Agriculture is plotting its next phase of growth with more farms, a licensing model for its technology and a new round of funding.

Gregg Curwin, founder and CEO of the Halifax vertical farming company, also says the company is focused ever more on machine learning and data analytics to help it produce the most nutritious local food possible.

Halifax-based TruLeaf aims to be a leader in sustainable agriculture through the use of vertical farming — which combines proven hydroponic technology with advancements in LED lighting and reclaimed rainwater to allow year-round production of plants indoors.

Vertical farming is nearly 30 times more efficient than traditional agriculture, uses as much as 95 per cent less water, and takes up less land.

Curwin told a panel discussion at the Big Data Congress last week that the company is now focusing on applying advanced technology to the process of growing plants indoors.

The Guelph plant — which is due to be completed in June, will be fully automated and TruLeaf is looking into using data to improve the process of growing nutritious food.

“The light bulb that’s going off for us is all about machine learning and data,” said Curwin.

Curwin said that in the controlled environment of its growing facilities, the company can monitor data produced over time from the creation of the seed to shipping grown food to the supermarket. Outdoors, a farmer can get 40 points of data in his or her career; TruLeaf can get 10,000 data points in 10 days at its indoor farms.

One example of TruLeaf’s experimentation is the work it has been doing with LED lighting.

The company is experimenting with how different plants grow under different light spectrums, and what lighting is best at specific phases of the growing process. It is even examining whether special lighting in a supermarket shelf can prolong the freshness of produce.

Curwin added that the company is investigating whether there is a direct link between adding certain greens to your diet and improving cognitive health.

It is interested in producing in Nova Scotia a vegetable prominent in West Africa, where dementia rates are really low.

“Can we make a defensible claim about the prevention of cognitive diseases?” he asked. “Making accurate claims is a significant goal of ours.”

The last 18 months have been busy ones for TruLeaf. It closed an $8.5-million financing round last December and has been working with Loblaw Companies, the parent company of Atlantic Superstores, on the development of its farms.

Appearing under the company’s GoodLeaf Farms brand, products grown in the company’s farm in Bible Hill are now available in a dozen Superstores spanning the three Maritime provinces.

According to the TruLeaf website, the products include broccoli shoots, kale shoots, daikon radish shoots, pea shoots, baby arugula and baby kale.

The company now has 38 employees in Nova Scotia.

“We’re eliminating low-level jobs and most of the jobs we are creating now are . . . in computer science, engineering and plant science,” said Curwin.

See original post here

For Immediate Release

November 7, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today it has been awarded a $1.2 million USD grant by the Department of Defense, Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program .

The Peer Reviewed Medical Research Program (PRMP) supports military health-related research that has the potential to make a strong impact on patient care. Appili will use the funds to develop a lead compound as a preclinical candidate for its ATI-1503 antibiotic program targeting drug-resistant, Gram-negative bacteria.

“Drug-resistant bacteria threaten a doctor’s ability to care for battlefield wounds among military service men and women,” said Kevin Sullivan, CEO of Appili Therapeutics. “We are honoured to have been selected for this PRMRP award, which helps us advance our most promising antibiotic candidate through the critical early stages of development.”

Drug-resistant bacteria constitute some of the highest threats to human health, with over 2 million infections and at least 23,000 deaths each year in the U.S. alone. These superbugs can present serious challenges in both battlefield situations, as well as in veterans’ hospitals, making it a priority research area for the Department of Defense (DOD).

ATI-1503 is a synthetic version of the naturally-occurring antibiotic called Negamycin.  Its broad spectrum activity allows it to tackle the most deadly Gram-negative bacteria, including Klebsiella pneumoniae, Acinetobactor baumannii, and Pseudomonas aeruginosa.  These are high priority pathogens for the Centers for Disease Control and Prevention and the World Health Organization because of the lack of effective antibiotic treatment options for the most resistant strains.

Appili’s expert drug development team will use the PRMRP funding to optimize the potency of ATI-1503 to effectively target Gram-negative bacteria. Because Gram-negative bacteria have two protective cellular walls, it is hard for existing antibiotics to penetrate.  ATI-1503 holds promise for treating these superbugs because it penetrates the double exterior membranes and attacks the protein generating machinery of the Gram-negative bacteria.


About the PRMRP Grant

This work is supported by the DOD Congressionally Directed Medical Research Programs through the Peer Reviewed Medical Research Program under Award No. W81XWH-17-1-0180. In conducting this research, the investigators will adhere to the laws of the United States and regulations of the Department of Agriculture, as well as the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. For more information, visit


About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat drug-resistant Gram-negative infections. For more information visit

Media Relations Contact:

Jennifer Cameron

T: 902-209-4704


Investor Relations Contact:

Kevin Sullivan, CEO, Appili Therapeutics

T: 902-442-4655


For Immediate Release

HALIFAX, Nova Scotia – October 30, 2017 – Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today that both the US Food and Drug Administration (FDA) and Health Canada have cleared its IND and CTA clinical investigation applications, respectively, to conduct a clinical trial of ATI-1501, a taste-masked antibiotic targeting anaerobic bacteria like Clostridium difficile. ATI-1501 has been optimized in an oral liquid suspension to provide patients who have difficulty swallowing with a more convenient alternative to the currently marketed metronidazole tablet.

Appili plans to conduct the ATI-1501 clinical study in Toronto, Ontario and will begin recruiting subjects in November 2017. The company expects to enroll approximately 40 healthy volunteers in this bioavailability study.

“Having both Health Canada and FDA authorization affirms our confidence in our regulatory and development strategy,” said Kevin Sullivan CEO of Appili Therapeutics. “We’re excited to take ATI-1501 into clinical trials because it brings us a step closer to offering physicians a new weapon to fight serious infections and improve patient compliance.”

ATI-1501 fulfills an unmet market need for millions of people with swallowing difficulties who have been prescribed metronidazole. These individuals, primarily children and the elderly, are not completing their full course of metronidazole tablets because of the extreme bitter taste and difficulty swallowing tablets. Poor patient compliance is leading to the spread of infection, recurrent infections, and antibiotic resistance, which makes treatment more complicated and expensive. As the mainstay for treating anaerobic bacterial infections, IMS Health reports that over 9.5 million prescriptions of metronidazole tablets are issued in the US each year.

Appili’s ATI-1501 oral liquid antibiotic candidate has been taste-masked to improve palatability and reduce issues with non-compliance. Once ingested, the well-studied and established antibiotic is designed to kill anaerobic bacteria by interfering with their DNA, which clears up the infection.

“We expect the completion of this clinical trial will set us up to file our new drug application in 2018 and advance our commercialization activities,” said Jamie Doran, Vice President of Drug Development of Appili Therapeutics.

Appili’s regulatory strategy involves registration using a 505(b)(2) pathway in the US, which is an abbreviated FDA pathway that allows the Company to reference safety and efficacy data of the original oral metronidazole tablet.


About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The Company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections that has been granted orphan drug status by the FDA. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections. These drug-resistant infections have been identified by the US Centers for Disease Control (CDC) and the World Health Organization as posing the highest threat to human health. For more information visit

Media Relations Contact:

Jennifer Cameron

T: 902-209-4704


Investor Relations Contact:

Kevin Sullivan, CEO, Appili Therapeutics

T: 902-442-4655


See original article here

The 2017 Game Changers awards were presented at the annual gala Monday night at the Westin Nova Scotia with an audience of more than 300 people.

The Halifax Partnership, which runs the Game Changers Youth Retention program, recognizes Halifax employers and connectors who demonstrate leadership in the industry through youth hires and meaningful learning opportunities. With the goal of keeping more youth workers in the province, the private-sector initiative aims to reduce the net annual average youth outmigration to zero by 2019.

Since Game Changers began, the net interprovincial outmigration of youth aged between 20 and 29 years old has improved from 1,500 to 222 between 2014 and 2015. Last year’s outmigration is estimated to be 231, showing the start of a positive trend for more youth staying and working in Nova Scotia.

“We at the Halifax Partnership are so proud of our province’s progress to date, and it is thanks to our business community,” said Ron Hanlon, president and CEO of the Halifax Partnership. “We’re making great strides, we need to keep the momentum going.”

After receiving more than 100 nominations, the annual awards are presented by TD Canada Trust, who named nine businesses in four categories as this year’s winners.


Best Youth Employer Awards


 Agada Biosciences Inc. (Small Business Category)


 Spring Loaded Technology (Medium Business Category)


 Citco (Canada) Inc. (Large Business Category)
Experiential Learning Awards

 Halifax Refugee Clinic (Small Business Category)

 Kinduct Technologies (Medium Business Category)

 Stantec Consulting Ltd. (Large Business Category)

Best Super

Connector Awards

 Chris O’Shea, Business Development Bank of Canada

 Shelagh McCorry, HSBC Bank Canada

Best Connector

Organization Award

 National Public Relations

2015 © Copyright - Bionova